|
|
Neuropsychological Profiles and Risk for Dementia-Related Disease in Mothers of Children with Autism Spectrum Disorder |
| 1F32AG079615-01 |
|
NIA |
2022 |
|
|
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) |
| 3U19AG068054-02S2 |
|
NIA |
2022 |
|
|
Health at Birth and Later Life Outcomes: Evaluating the Returns to Policy-Driven Early Health Investments |
| 5R01AG059731-05 |
|
NIA |
2022 |
|
|
GM-CSF/sargramostim treatment to improve cognition in Down syndrome |
| 5R61AG074859-02 |
|
NIA |
2022 |
|
|
Brain Imaging Core
[Parent Title: Waisman Center Intellectual and Developmental Disabilities Research Center] |
| 1 F32 AG071308-01 |
|
NIA |
2021 |
|
|
A patient-specific computational technique to predict spine injury risks associated with physical activities |
| 1 K25 AG068368-01A1 |
|
NIA |
2021 |
|
|
Individualizing Anticoagulant use in Older Adults with Atrial Fibrillation |
| 1 K76 AG074919-01 |
|
NIA |
2021 |
|
|
South Texas Alzheimer’s Disease Center Population Neuroscience |
| 1 P30 AG066546-01A1 |
|
NIA |
2021 |
|
|
Core I: Latino Core |
| 1 P30 AG072975-01 |
|
NIA |
2021 |
|
|
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease |
| 1 R01 AG071151-01 |
|
NIA |
2021 |
